Lennox-Gastaut Syndrome (LGS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Lennox-Gastaut Syndrome (LGS) Market Outlook

Thelansis’s “Lennox-Gastaut Syndrome (LGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lennox-Gastaut Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lennox-Gastaut Syndrome (LGS) Overview

Lennox-Gastaut syndrome (LGS) is a rare and severe form of childhood epilepsy, falling into the category of severe infantile epileptic syndromes, which includes epileptic neonatal encephalopathy with suppression-burst, West syndrome and severe myoclonic epilepsy of infancy. Typically, LGS manifests with seizures starting in early childhood, typically between ages 3 and 5. It is characterized by significant physical risks for affected children and teenagers, including frequent falls, injuries, and cognitive impairment, severely impacting their quality of life. While LGS may affect children with infantile spasms or underlying brain issues, it can also have an unknown cause (idiopathic). Almost always, antecedent conditions linked to LGS involve the cerebral cortex, with phenomena of LGS stemming from the cerebral cortex and corpus callosum. LGS is most commonly associated with damage to both frontal lobes. However, any brain damage can potentially lead to LGS, and the lack of specificity complicates understanding its neurophysiological mechanisms. Individuals with LGS, including children, adolescents, and adults, experience various types of seizures that vary from person to person. These include:

1. Body stiffening, upward eye gaze, dilated pupils, and altered breathing patterns characterize tonic seizures.
2. Atypical absences, which involve staring spells.
3. Atonic seizures result in a brief loss of muscle tone and potential abrupt falls.
4. Myoclonic seizures cause sudden muscle jerks.
5. Generalized tonic-clonic seizures are marked by muscle stiffness and rhythmic jerking.

In addition to medications approved for general seizure treatment, there are specific drugs approved for managing seizures in individuals with LGS, such as clobazam, rufinamide, topiramate, lamotrigine, felbamate, cannabidiol, fenfluramine, and clonazepam.

• The incidence of Lennox-Gastaut syndrome is extremely low, accounting for approximately 1% of childhood epilepsies in children under 10 years old. The majority of LGS cases, around 68%, occur in children under 18, with the remaining 38% affecting adults. Notably, remission rates are particularly low for LGS, with roughly 50-60% of children who initially experience infantile spasms going on to develop other types of seizures.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: